PSMA PET in Prostate Cancer

Molecular imaging with PET using an increasing list of biologically relevant radiotracers is paving the way for precision and personalized medicine in prostate cancer (1). Prostate-specific membrane antigen (PSMA) has received a resurgence of attention as a useful biomarker in the imaging evaluation of prostate cancer with PET. PSMA is a type II, 750-amino-acid integral membrane glycoprotein (100–120 kDa), with a 19-amino-acid intracellular component, a 24-amino-acid intramembrane segment, and a large 707-amino-acid extracellular domain (2). It has several enzymatic functions and is known to be upregulated in castrate-resistant and metastatic prostate cancer (3). Despite what the name suggests, PSMA is not specific to the prostate gland and is expressed in other normal (e.g., salivary glands, duodenal mucosa, subset of proximal renal tubular cells, and subpopulation of neuroendocrine cells in the colonic crypts) and neoplastic (e.g., subtypes of transitional cell carcinoma, renal cell carcinoma, colon carcinoma, and peritumoral and endotumoral endothelial cell of neovasculature) tissues (4). There is no known natural ligand for PSMA, and the reasons for its upregulation in prostate cancer remain unclear. PSMA undergoes constitutive internalization and as such can serve not only as an imaging biomarker but also for targeted therapy—in other words, PSMA may be useful as a target for theranostic agents (5).

The commercially available ¹¹¹In-capromab pendetide targets the internal epitope of PSMA with radiolabeled mouse monoclonal antibody 7E11. However, this agent is accessible only to its target in dying or dead cells and has been technically demanding to perform, with only moderate diagnostic performance in men at high risk for lymph node or soft-tissue metastases and negative bone scintigraphy. The recently developed PET radiotracers primarily target the extracellular moiety of the PSMA (hence detecting viable cells) and include ¹¹C- (half-life, 20.3 min), ¹⁸F- (half-life, 109.8 min), ⁶⁸Ga- (half-life, 67.7 min), ⁸⁹Zr- (half-life, 78.4 h), ⁶⁴Cu- (half-life, 12.7 h), and ⁸⁶Y- (half-life, 14.7 h) labeled agents that involve antibodies, antibody fragments, aptamers, and PSMA inhibitors (2). In particular, many publications are now appearing in literature on the potential diagnostic utility of the Glu-NH-CO-NH-Lys-(Ahx)-[⁶⁸Ga-HBEDD-CC] conjugate (abbreviated as ⁶⁸Ga-PSMA, which binds the motif glutamate-urea-lysine with the chelator HBED-CC) in prostate cancer. The normal biodistribution of this tracer shows intense uptake in salivary glands and kidneys and moderate uptake in lacrimal glands, liver, spleen, and intestines (6). False-negative results may include prostate tumors with neuroendocrine differentiation, small tumors, and tumors located next to areas with high physiologic tracer uptake (7). False-positive results have been reported with physiologic uptake in the celiac ganglia (8).

In the primary tumor setting, a single clinical case report using a hybrid PET/MR imaging system showed high tracer localization, T2 hypointensity, and restricted diffusion at the tumor site (9). The small foci of benign prostate hyperplasia demonstrated diffuse diffusion restriction but no abnormal tracer accumulation. Although additional experience will be needed in the primary tumor setting, ⁶⁸Ga-PSMA PET/MR imaging may provide sufficient imaging information to guide biopsy and delivery of focal therapy to the dominant aggressive lesion.

In the May 2015 issue of The Journal of Nuclear Medicine, Eiber et al. from Germany reported on a retrospective analysis of ⁶⁸Ga-PSMA PET/CT in 248 patients with biochemical recurrence (serum PSA range, 0.2–59.4 ng/mL; median, 1.99 ng/mL) of prostate cancer after radical prostatectomy (10). One board-certified nuclear medicine physician and 1 board-certified radiologist interpreted PET and CT images, respectively, and separately, with a final consensus interpretation. The standard of reference for the PET imaging findings was as usual mostly based on clinical or other imaging follow-up. The authors reported lesion detection rates that increased with increasing serum PSA level. The lesion detection rate for the range of key clinical interest in the low serum PSA range (0.2–0.5 ng/mL) was 58%. A higher detection rate was also noted with higher PSA velocity but not with shorter PSA doubling time. The authors also found a higher lesion detection rate in patients with higher primary tumor Gleason score, but no statistically significant association was noted with regards to the use of androgen-deprivation therapy. One key question that remains unanswered by this report is the unique contribution of the nonstandard ⁶⁸Ga-PSMA PET/CT over conventional imaging in the setting of biochemical recurrence after radical prostatectomy. Although this was tangentially addressed in this report (33% of lesions were detected only on PET), a prospective study with well-defined inclusion criteria involving only patients with PSA relapse and no conventional imaging evidence of locally recurrent and metastatic disease would clarify the distinctive role of ⁶⁸Ga-PSMA in this important clinical setting that then can be compared with the reported results for other relevant radiotracers. Such study design will help to elucidate the competitive advantage of ⁶⁸Ga-PSMA in biochemical recurrence of prostate cancer. In another study from the same group of investigators, it has been noted that ⁶⁸Ga-PSMA may have an advantage over ¹⁸F-fluorocholine (11). However, additional comparative studies will be needed to ratify this early observation and to establish the clinical relevance of potentially detecting more lesions with ⁶⁸Ga-PSMA PET/CT in comparison to radiolabeled choline PET/CT.

The other finding in this study was that there was no statistically significant association between the lesion detection rate and androgen-deprivation treatment. This finding is probably related to statistical power issues because it is contrary to prior reports that have demonstrated higher PSMA expression in tumor cells exposed to antihormonal treatment (12,13). Future prospective studies will be needed to examine how ⁶⁸Ga-PSMA behaves in the treatment response assessment setting with various therapy regimens (14). This will likely depend on the extent that PSMA expression may be affected by different therapies aside from cell death (which in turn can also be imaged with those tracers that target the internal epitope of PSMA). In summary, ⁶⁸Ga-PSMA is a noteworthy radiotracer with high potential for diagnostic utility in prostate cancer. Moreover, appropriate radionuclide substitutions may provide opportunity for targeted radioisotope therapy (15). Additional prospective clinical studies in well-defined patient cohorts, clinical settings, and expected outcomes will be needed to confidently establish the role of ⁶⁸Ga-PSMA as a major contender radiotracer in the imaging evaluation of prostate cancer with PET.

• © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

• Received for publication April 29, 2015.
• Accepted for publication April 30, 2015.